Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia

Glucocorticoid (GC) resistance is a poor prognostic factor in T‐cell acute lymphoblastic leukaemia (T‐ALL). Interleukin‐7 (IL‐7) mediates GC resistance via GC‐induced upregulation of IL‐7 receptor (IL‐7R) expression, leading to increased pro‐survival signalling. IL‐7R reaches the cell surface via the secretory pathway, so we hypothesized that inhibiting the translocation of IL‐7R into the secretory pathway would overcome GC resistance. Sec61 is an endoplasmic reticulum (ER) channel that is required for insertion of polypeptides into the ER. Here, we demonstrate that KZR‐445, a novel inhibitor of Sec61, potently attenuates the dexamethasone (DEX)‐induced increase in cell surface IL‐7R and overcomes IL‐7‐induced DEX resistance.

[1]  J. Cools,et al.  Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies , 2021, Pharmaceuticals.

[2]  A. Olshen,et al.  Glucocorticoids paradoxically facilitate steroid resistance in T-cell acute lymphoblastic leukemias and thymocytes. , 2020, The Journal of clinical investigation.

[3]  Priya S. Shah,et al.  Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis , 2018, Cell.

[4]  W.-J. Liu,et al.  Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. , 2018, European review for medical and pharmacological sciences.

[5]  K. Vermeire,et al.  Inhibitors of protein translocation across membranes of the secretory pathway: novel antimicrobial and anticancer agents , 2018, Cellular and Molecular Life Sciences.

[6]  J. Taunton,et al.  JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias , 2017, Leukemia.

[7]  D. Teachey,et al.  T-cell acute lymphoblastic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.

[8]  Yazmin P. Carrasco,et al.  Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum , 2014, Oncogene.

[9]  M. Loh,et al.  T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .

[10]  E. Hartmann,et al.  Signal Peptide-Binding Drug as a Selective Inhibitor of Co-Translational Protein Translocation , 2014, PLoS biology.

[11]  Lanju Zhang,et al.  A New Bliss Independence Model to Analyze Drug Combination Data , 2014, Journal of biomolecular screening.

[12]  A. Ferrando,et al.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia , 2011, Nature Genetics.

[13]  J. Taunton,et al.  Secretory protein profiling reveals TNF-α inactivation by selective and promiscuous Sec61 modulators. , 2011, Chemistry & biology.

[14]  M. Loh,et al.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.

[15]  J. Taunton,et al.  A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum , 2005, Nature.

[16]  R. Kofler,et al.  Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance , 2004, Cell Death and Differentiation.

[17]  A. Johnson,et al.  The translocon: a dynamic gateway at the ER membrane. , 1999, Annual review of cell and developmental biology.